Page 1

Exhibit 99.1 Galapagos refocuses pipeline and rightsizes operations First three months 2021 financial results : . • Group revenues and other income of € 124.2 million Operating loss of € 50.8 million Net profit of € 9.4 million Cash and current financial investments of € 5.1 billion on 31 March 2021 Refocused clinical pipeline by critically examining risk profile and breadth Galápagos • Filgotinib launch in Europe on track • Initiated € 150 million savings program Webcast presentation tomorrow , 07 May 2021 , at 14.00 CET / 8 AM ET , www.glpg.com , +32 2 793 38 47 , code 5042688 Mechelen , Belgium ; 06 May 2021 , 22.01 CET ; regulated information – Galapagos NV ( Euronext & NASDAQ : GLPG ) announces its unaudited Q1 results and operational highlights , which are further detailed in the Q1 2021 report available on the Galapagos website , www.glpg.com . “ These last months , we completed a review of our portfolio and development plans with the goal to select a more risk - balanced pipeline . We decided to retain our focus on novel targets to address unmet medical needs in inflammation , fibrosis , and kidney diseases . We also remain fully committed to the launch of Jyseleca in Europe . Moving forward with confidence , we decided to : • Refocus our clinical pipeline by critically examining its risk profile and breadth ; • Cut significant cost in the organization to support this re - sized pipeline development ; • Task our business development team to identify and execute on a transformative opportunity . We believe that our strong cash position , expert teams , and solid scientific foundation position us well for future growth , ” said Onno van de Stolpe , CEO of Galapagos . Refocused pipeline In the revision exercise , Galapagos set goals to focus and adjust the overall risk profile of its clinical pipeline . Consequently , we prioritized those assets with what we believe have enhanced chances of clinical success in our core therapeutic areas . As such , we announce : • We are testing our lead Toledo program ‘ 3970 , a SIK2 / 3 inhibitor , in five Proof of Concept studies in different indications , and pending the outcome of the studies , we plan to roll out our further development plans in the second half of the year ; We selected an additional molecule from our Toledo program , SIK2 / 3 inhibitor $ 4876 , as a candidate to accelerate from preclinical phase into clinical development ; • We aim to progress our TYK2 inhibitor ‘ 3667 into Phase 2b ; • We selected chitinase inhibitor ' 4617 to progress to Phase 2 in IPF and decided to stop development of our other IPF molecule ' 1205 ; • We stopped further work on ‘ 4059 for metabolic disease , given that this is not a core therapeutic area ;